Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC.

Cancer letters·2025
Same author

Dark Energy Survey Year 1 Results: Cosmological Constraints from Cluster Abundances, Weak Lensing, and Galaxy Correlations.

Physical review letters·2021
Same author

Constraints on Dark Matter Properties from Observations of Milky Way Satellite Galaxies.

Physical review letters·2021
Same author

Detection of Cross-Correlation between Gravitational Lensing and γ Rays.

Physical review letters·2020
Same author

Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Detection of CMB-Cluster Lensing using Polarization Data from SPTpol.

Physical review letters·2019
Same journal

Corrigendum.

Tissue antigens·2015
Same journal

Nomenclature for factors of the HLA system, update September 2015.

Tissue antigens·2015
Same journal

Nomenclature for factors of the HLA system, update August 2015.

Tissue antigens·2015
Same journal

Nomenclature for factors of the HLA system, update July 2015.

Tissue antigens·2015
Same journal

Four amino acid exchanges located in the alpha-2 domain specify the novel HLA-B*50:20 allele.

Tissue antigens·2015
Same journal

A novel HLA-A*02 variant, HLA-A*02:575, detected in a Taiwanese bone marrow hematopoietic stem cell donor.

Tissue antigens·2015
See all related articles

Related Experiment Video

Updated: May 25, 2026

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
07:18

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Published on: April 11, 2011

Targeting HLA class I expression to increase tumor immunogenicity.

A B del Campo1, J Carretero, N Aptsiauri

  • 1Servicio de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Granada, Spain.

Tissue Antigens
|February 8, 2012
PubMed
Summary
This summary is machine-generated.

Cancer immunotherapy faces challenges due to tumor cells evading detection by downregulating human leukocyte antigen (HLA) class I. Restoring HLA class I expression is crucial for effective anti-tumor immunity and successful cancer treatment.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
08:27

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

Related Experiment Videos

Last Updated: May 25, 2026

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
07:18

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Published on: April 11, 2011

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
08:27

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

Area of Science:

  • Tumor immunology
  • Cancer immunotherapy
  • Molecular oncology

Background:

  • Host immune system interaction with cancer is key in tumor immunology.
  • Human leukocyte antigen (HLA) class I-restricted CD8+ T cells recognize tumor-associated antigens (TAA) for cancer cell destruction.
  • Cancer immunotherapy aims to enhance anti-tumor immunity but faces limited clinical success.

Purpose of the Study:

  • To review the mechanisms of tumor immune escape, focusing on human leukocyte antigen (HLA) class I loss.
  • To discuss the implications of HLA class I alterations on T-cell-mediated tumor rejection and immunotherapy outcomes.
  • To highlight the importance of monitoring and correcting HLA class I defects in cancer treatment.

Main Methods:

  • Review of experimental data from mouse cancer models and human metastatic tumors.
  • Analysis of mechanisms underlying tumor cell immune escape, including HLA class I downregulation.
  • Discussion of potential strategies, such as gene therapy, to overcome HLA class I loss.

Main Results:

  • Tumor cells escape immune detection through mechanisms like loss or downregulation of HLA class I antigens.
  • Both regulatory ('soft') and structural/irreversible ('hard') defects contribute to HLA class I alterations.
  • Structural defects in HLA class I expression significantly impact T-cell-mediated tumor rejection and immunotherapy efficacy.

Conclusions:

  • HLA class I alterations are a major obstacle in cancer immunotherapy, leading to immune escape and lack of clinical benefit.
  • Monitoring and correcting HLA class I defects are essential for improving T-cell-mediated anti-tumor immunity.
  • Strategies like gene therapy offer potential to restore HLA class I expression and enhance cancer treatment outcomes.